Catalyst OrthoScience's Shoulder Fracture System Receives FDA Clearance

Key Insights

• Catalyst OrthoScience has received FDA 510(k) clearance for its innovative shoulder fracture system, expanding its comprehensive orthopedic portfolio.
• The Catalyst fracture system is specifically designed for reverse shoulder arthroplasty in patients suffering from proximal humerus fractures.
• The system addresses the critical challenges of tuberosity fixation and healing, which are key concerns in treating proximal humerus fractures.

Catalyst OrthoScience has announced that it received FDA 510(k) clearance for its Catalyst shoulder fracture system. The system is designed to aid surgeons in reverse shoulder arthroplasty (RSA) procedures for patients who have experienced proximal humerus fractures (PHFs). This clearance allows Catalyst to broaden its offerings in the orthopedics market.

According to Catalyst, the use of RSA for treating PHFs is on the rise. A significant challenge in treating PHFs is ensuring adequate tuberosity fixation and healing. Traditional reverse implants are typically designed for shoulder arthritis, but fractures present different objectives for the surgeon.

Addressing Proximal Humerus Fracture Challenges

Dr. Steven Goldberg, founder and chief medical officer of Catalyst, stated that the company engineered a solution that specifically addresses the complexities of proximal humerus fractures in an efficient and novel way. The Catalyst fracture system aims to improve outcomes in these challenging cases.

Leadership Perspective

Catalyst OrthoScience CEO Carl O’Connell noted that the addition of the Catalyst fracture system provides surgeons with a more comprehensive set of tools to help a broader range of patients. He emphasized that this product is key to the company's strategy and strengthens its leadership in the orthopedics market.